Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 29, 2024Journal of Medicinal Chemistry

Radioactive ADME Demonstrates ARV-110’s High Druggability Despite Low Oral Bioavailability

View Full Paper
Ask AI
Bookmark
Share

Authors

YHYifei HeXi'an University of Architecture and TechnologyYZYuandong ZhengChinese Academy of SciencesCZChenggu ZhuWuXi AppTec (China)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

He et al. (2024) studied this question.

synapsesocial.com/papers/68e5ea28b6db64358757e6c9https://doi.org/10.1021/acs.jmedchem.4c01104
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.2019 · 216 citations
  2. 2Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).2022 · 201 citations
  3. 3Waste disposal—An attractive strategy for cancer therapy2017 · 284 citations